Category News

BlueRock Begins Phase III Trial of Cell Therapy Bemdaneprocel with First Parkinson’s Patient Treated

First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel  BlueRock Therapeutics LP, a clinical-stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, today announced that the first patient has…

Read MoreBlueRock Begins Phase III Trial of Cell Therapy Bemdaneprocel with First Parkinson’s Patient Treated

Lexicon Supports Phase III Advancement of Non-Opioid Pain Therapy Following Post-Hoc Analysis

Lexicon Backs Phase III Go Decision for Non-Opioid Pain Med With Post-Hoc AnalysisSupporting Lexicon Pharmaceuticals’ decision to advance the non-opioid analgesic pilavapadin into late-stage development—despite a topline miss in March—is an “improving” regulatory environment for non-addictive options for chronic pain,…

Read MoreLexicon Supports Phase III Advancement of Non-Opioid Pain Therapy Following Post-Hoc Analysis

Key Challenges in AAD Sourcing: Ensuring GMP Compliance, Reliable Supply, and Quality Control

Key challenges in AAD sourcing: GMP compliance, supply reliability & quality control Amino acid derivatives (AADs) are essential starting materials for solid-phase peptide synthesis, crucial for the development of peptide-based therapeutics in areas like oncology, metabolic disorders, and infectious diseases. As…

Read MoreKey Challenges in AAD Sourcing: Ensuring GMP Compliance, Reliable Supply, and Quality Control

Intellia Completes Phase 3 HAELO Study Enrollment for Lonvo-z in Hereditary Angioedema

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced it has completed enrollment…

Read MoreIntellia Completes Phase 3 HAELO Study Enrollment for Lonvo-z in Hereditary Angioedema

Saphnelo Self-Administration TULIP-SC Phase III Trial Hits Primary Endpoint in Lupus Patients

Saphnelo self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis Positive high-level results from a pre-specified interim analysis of the Phase III TULIP-SC trial in patients with systemic lupus erythematosus…

Read MoreSaphnelo Self-Administration TULIP-SC Phase III Trial Hits Primary Endpoint in Lupus Patients

Republicans Intensify Pressure as Monarez Makes Explosive Allegations Against Kennedy

Republicans Ratchet Up Pressure as Monarez Levels Damning Allegations Against Kennedy During a hearing in front of the Senate’s HELP committee, Susan Monarez addressed her controversial firing and recalled a conversation where Health Secretary Robert F. Kennedy Jr. allegedly said…

Read MoreRepublicans Intensify Pressure as Monarez Makes Explosive Allegations Against Kennedy